Figure 3.
The position of PVR function in the JNK pathway. (A) The PDGFRα/PVR-Myc cell line was incubated in the absence (NT, lanes 3 and 4) or presence (lanes 1 and 2) of dsRNAs representing slpr or hep. After 2 days, the cells were serum-starved, and expression of the chimeric molecule was then induced with 100 mg/ml CuSO4 (after a medium change, the same dsRNA was supplied again to each sample). The next day, the cells were either left untreated (lane 4) or treated (lanes 1–3) with 100 ng/ml PDGF-BB for 20 min. Then, cellular extracts were prepared and subjected to Western analysis using anti-pJNK and anti-JNK1 antibodies. (B) Suppression or enhancement of the thorax phenotypes of pnr>Pvr-IRs by mutations implicated in the JNK pathway. Classes I–III correspond to phenotypes shown in Figure 1F–H, respectively.